表紙
市場調查報告書

CAR-T細胞療法的全球市場:佔有率、市場規模、產業分析 - 各標的抗原、適應症、地區 2020年∼2026年

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2020 - 2026

出版商 Polaris Market Research 商品編碼 873206
出版日期 內容資訊 英文 108 Pages
商品交期: 最快1-2個工作天內
價格
CAR-T細胞療法的全球市場:佔有率、市場規模、產業分析 - 各標的抗原、適應症、地區 2020年∼2026年 CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2020 - 2026
出版日期: 2020年02月01日內容資訊: 英文 108 Pages
簡介

全球CAR-T細胞療法市場在2020年∼2026年間,預測將以34.5%的年複合成長率發展,至2026年預計將達到89億2,000萬美元。CAR-T細胞療法,是取出患者自己的T細胞,應用遺傳基因技術改造T細胞使其攻擊癌症細胞的治療方法。許多企業為了獲得更高的佔有率開始投資CAR-T細胞療法。

本報告提供全球CAR-T細胞療法市場調查,市場概要,各標的抗原、適應症、各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,產業趨勢,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 市場概要與範圍

  • 調查目的和範圍
  • 調查的前提
  • 調查手法
  • 重要點
  • 相關利益者

第2章 摘要整理

  • 市場定義
  • 市場區隔

第3章 CAR-T細胞療法市場考察

  • CAR-T細胞療法:產業概述
  • 生態系統分析
  • 市場動態
  • 波特的五力分析
  • PEST分析
  • 產業趨勢
  • 競爭排行榜分析
  • CAR-T細胞的開發時間軸
  • CAR-T細胞的製造流程
  • CAR-T細胞療法的副作用
  • 固體癌的標的抗原
  • CAR-T細胞療法的臨床試驗
  • 合併、收購、夥伴關係、合作
  • CAR-T細胞療法新的創新

第4章 CAR-T細胞療法市場:各標的抗原

  • 市場佔有率:各標的抗原(成果值、預測值)
  • CD19/CD22
    • 市場規模(成果值、預測值)
    • 市場規模:各地區(成果值、預測值)
  • BCMA
  • 其他 (MUC16,L1CAM,ROR1,EGFRvIII,PSCA,NKR-2,IL13Ra2,LewisY)

第5章 CAR-T細胞療法市場:各適應症

  • 市場規模:各適應症
  • 瀰漫性大型B細胞淋巴癌(DLBCL)
    • 市場規模(成果值、預測值)
    • 市場規模:各地區(成果值、預測值)
  • 急性淋巴芽球性白血病(ALL)
  • 慢性淋巴性白血病(CLL)
  • 多發性骨髓瘤(MM)
  • 濾泡型淋巴瘤(FL)
  • 其他

第6章 CAR-T細胞療法市場:各地區

  • 主要調查結果
  • 美國
    • 市場規模:各標的抗原(成果值、預測值)
    • 市場規模:適應症(成果值、預測值)
  • 歐洲
  • 日本
  • 其他地區

第7章 企業簡介

  • Amgen Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bluebird Bio
  • Caribou Biosciences, Inc.
  • Celgene Corporation (acquired by Bristol-Myers Squibb)
  • Cellectis
  • Celyad
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Johnson & Johnson
  • Mereck KGaA
  • Nanjing Legend Biotechnology Co., Ltd.
  • Noile-Immune Biotech
  • Novartis International AG
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Servier Laboratories

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PM1389

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research. The report "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 - 2026" provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients' immune cells to fight cancer. The WBCs (white blood cells) are extracted - reengineered - injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.

According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

Polaris Market research has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region

CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 - 2026)

CD19/CD22

BCMA (B-Cell Maturation Antigen)

Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Rα2, LewisY)

CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 - 2026)

Diffuse Large B-Cell Lymphoma (DLBCL)

Acute Lymphoblastic Leukemia (ALL)

Chronic Lymphocytic Leukemia (CLL)

Multiple Myeloma (MM)

Follicular Lymphoma (FL)

Others

CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 - 2026)

U.S.

Europe

Japan

Rest of the World

Table of Contents

1. Overview and Scope

  • 1.1. Research goal & scope
  • 1.2. Research assumptions
  • 1.3. Research Methodology
    • 1.3.1. Primary data sources
    • 1.3.2. Secondary data sources
  • 1.4. Key take-aways
  • 1.5. Stakeholders

2. Executive Summary

  • 2.1. Market Definition
  • 2.2. Market Segmentation

3. CAR-T Cell Therapy Market - Premium Insights

  • 3.1. CAR-T Cell Therapy- Industry snapshot
  • 3.2. CAR-T Cell Therapy- Ecosystem analysis
  • 3.3. CAR-T Cell Therapy Market dynamics
    • 3.3.1. CAR-T Cell Therapy- Market Forces
      • 3.3.1.1. CAR-T Cell Therapy Market driver analysis
      • 3.3.1.2. CAR-T Cell Therapy Market restraint/challenges analysis
      • 3.3.1.3. CAR-T Cell Therapy Market opportunity analysis
  • 3.4. Industry analysis - Porter's five force analysis
  • 3.5. CAR-T Cell Therapy Market PEST analysis, 2019
  • 3.6. CAR-T Cell Therapy Industry trends
  • 3.7. Competitive Ranking Analysis
  • 3.8. Timeline of CAR-T Cell Therapy Development
  • 3.9. CAR-T Cell Manufacturing Process
  • 3.10. Side-effects of CAR-T Cell
  • 3.11. Antigens targeting solid tumors
  • 3.12. Clinical trials Landscape for CAR-T
  • 3.13. Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
  • 3.14. New Innovations in CAR-T therapies

4. CAR-T Cell Therapy Market Size and Forecast 2017 - 2026 by Target Antigen

  • 4.1. Key findings
  • 4.2. CD19/CD22
    • 4.2.1. Global CD19/CD22 market estimates & forecast, 2017 - 2026
    • 4.2.2. Global CD19/CD22 market estimates & forecast, by region, 2017 - 2026
  • 4.3. BCMA (B-Cell Maturation Antigen)
    • 4.3.1. Global BCMA market estimates & forecast, 2017 - 2026
    • 4.3.2. Global BCMA market estimates & forecast, by region, 2017 - 2026
  • 4.4. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
    • 4.4.1. Global Other Target Antigen market estimates & forecast, 2017 - 2026
    • 4.4.2. Global Other Target Antigen market estimates & forecast, by region, 2017 - 2026

5. CAR-T Cell Therapy Market Size and Forecast by Indication

  • 5.1. Key findings
  • 5.2. Diffuse Large B-Cell Lymphoma (DLBCL)
    • 5.2.1. Global DLBCL market estimates & forecast, 2017 - 2026
    • 5.2.2. Global DLBCL market estimates & forecast, by region, 2017 - 2026
  • 5.3. Acute Lymphoblastic Leukemia (ALL)
    • 5.3.1. Global ALL market estimates & forecast, 2017 - 2026
    • 5.3.2. Global ALL market estimates & forecast, by region, 2017 - 2026
  • 5.4. Chronic Lymphocytic Leukemia (CLL)
    • 5.4.1. Global CLL market estimates & forecast, 2017 - 2026
    • 5.4.2. Global CLL market estimates & forecast, by region, 2017 - 2026
  • 5.5. Multiple Myeloma (MM)
    • 5.5.1. Global MM market estimates & forecast, 2017 - 2026
    • 5.5.2. Global MM market estimates & forecast, by region, 2017 - 2026
  • 5.6. Follicular Lymphoma (FL)
    • 5.6.1. Global FL market estimates & forecast, 2017 - 2026
    • 5.6.2. Global FL market estimates & forecast, by region, 2017 - 2026
  • 5.7. Others
    • 5.7.1. Global Other indications market estimates & forecast, 2017 - 2026
    • 5.7.2. Global Other indications market estimates & forecast, by region, 2017 - 2026

6. CAR-T Cell Therapy Market Size and Forecast by Regions

  • 6.1. Key findings
  • 6.2. U.S.
    • 6.2.1. U.S. CAR-T Cell Therapy Market by Target Antigen, 2017-2026
    • 6.2.2. U.S. CAR-T Cell Therapy Market by Indication, 2017 - 2026
  • 6.3. Europe
    • 6.3.1. Europe CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
    • 6.3.2. Europe CAR-T Cell Therapy Market by Indication, 2017 - 2026
  • 6.4. Japan
    • 6.4.1. Japan CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
    • 6.4.2. Japan CAR-T Cell Therapy Market by Indication, 2017 - 2026
  • 6.5. Rest of the World
    • 6.5.1. RoW CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
    • 6.5.2. RoW CAR-T Cell Therapy Market by Indication, 2017 - 2026

7. Company Profiles

  • 7.1. Amgen Inc. (US)
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Benchmarking
    • 7.1.4. Recent Developments
  • 7.2. Bellicum Pharmaceuticals, Inc. (US)
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Benchmarking
    • 7.2.4. Recent Developments
  • 7.3. Bluebird Bio (US)
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Benchmarking
    • 7.3.4. Recent Developments
  • 7.4. Caribou Biosciences, Inc. (US)
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Benchmarking
    • 7.4.4. Recent Developments
  • 7.5. Celgene Corporation (US) (acquired by Bristol-Myers Squibb)
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Benchmarking
    • 7.5.4. Recent Developments
  • 7.6. Cellectis (France)
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Benchmarking
    • 7.6.4. Recent Developments
  • 7.7. Celyad (Belgium)
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Benchmarking
    • 7.7.4. Recent Developments
  • 7.8. Gilead Sciences, Inc. (US)
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Product Benchmarking
    • 7.8.4. Recent Developments
  • 7.9. Intellia Therapeutics (US)
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Product Benchmarking
    • 7.9.4. Recent Developments
  • 7.10. Johnson & Johnson (US)
    • 7.10.1. Overview
    • 7.10.2. Financials
    • 7.10.3. Product Benchmarking
    • 7.10.4. Recent Developments
  • 7.11. Mereck KGaA (Germany)
    • 7.11.1. Overview
    • 7.11.2. Financials
    • 7.11.3. Product Benchmarking
    • 7.11.4. Recent Developments
  • 7.12. Nanjing Legend Biotechnology Co., Ltd. (China)
    • 7.12.1. Overview
    • 7.12.2. Financials
    • 7.12.3. Product Benchmarking
    • 7.12.4. Recent Developments
  • 7.13. Noile-Immune Biotech (Japan)
    • 7.13.1. Overview
    • 7.13.2. Financials
    • 7.13.3. Product Benchmarking
    • 7.13.4. Recent Developments
  • 7.14. Novartis International AG (Swiss)
    • 7.14.1. Overview
    • 7.14.2. Financials
    • 7.14.3. Product Benchmarking
    • 7.14.4. Recent Developments
  • 7.15. Pfizer Inc. (US)
    • 7.15.1. Overview
    • 7.15.2. Financials
    • 7.15.3. Product Benchmarking
    • 7.15.4. Recent Developments
  • 7.16. Sangamo Therapeutics, Inc. (US)
    • 7.16.1. Overview
    • 7.16.2. Financials
    • 7.16.3. Product Benchmarking
    • 7.16.4. Recent Developments
  • 7.17. Servier Laboratories (France)
    • 7.17.1. Overview
    • 7.17.2. Financials
    • 7.17.3. Product Benchmarking
    • 7.17.4. Recent Developments